Rectal STI Testing: Indications and Symptoms
Rectal STI testing should be performed annually in all men who have sex with men (MSM) who engage in receptive anal intercourse, with screening every 3-6 months for those at highest risk (multiple/anonymous partners, drug use during sex), and importantly, most rectal STIs are asymptomatic so testing should not wait for symptoms to appear. 1
Key Indications for Rectal STI Testing
Population-Based Screening (Asymptomatic)
Men who have sex with men (MSM):
- Annual screening for rectal chlamydia and gonorrhea based on receptive anal intercourse exposure 1
- Increase frequency to every 3-6 months if high-risk behaviors present:
- Multiple or anonymous partners
- Sex in conjunction with illicit drug use
- Partners who engage in these activities 1
Other populations:
- Consider in anyone reporting receptive anal intercourse regardless of sexual orientation 2, 3
- Heterosexual individuals with changing sexual practices increasingly affected 2
- HIV-infected patients warrant screening given high asymptomatic carriage rates 4
Symptomatic Presentations
Critical caveat: The majority of rectal STIs are asymptomatic - only 30-60% of infections produce symptoms, making symptom-based testing inadequate 5, 4. When symptoms do occur, watch for:
Common symptoms (in order of frequency):
- Rectal itching (most common - present in 4.6% of positive cases) 5
- Rectal pain or discomfort
- Pain on defecation
- Blood in stool
- Rectal discharge (rare, <1% of cases despite being classically described) 5
Duration and severity:
- Symptoms typically mild and brief (median 1 week for chlamydia/gonorrhea, 3 weeks for M. genitalium) 5
- Symptoms are 3 times more likely when infection present (8.1% vs 3.9% of weeks) 5
Important Clinical Pitfalls
Do not rely on symptoms alone - 62-70% of rectal chlamydia and gonorrhea infections are completely asymptomatic 5, 4. Asymptomatic carriage results from bacterial adaptation to rectal tissues and attenuated local immune responses 6.
Diagnostic mimicry: Rectal STIs can endoscopically mimic inflammatory bowel disease or malignancy, leading to misdiagnosis 2. Maintain high index of suspicion in at-risk populations.
Screen for coinfections: When one rectal STI is identified, test for others including HIV, hepatitis B/C, and syphilis 2, 4.
Testing Approach
- Self-collected rectal swabs are effective and acceptable for screening 4
- Use nucleic acid amplification tests (NAATs) for chlamydia, gonorrhea, and M. genitalium 5, 4
- Test all three anatomic sites (pharyngeal, rectal, urethral) based on sexual practices in MSM 1
Retest 3 months after treatment regardless of partner treatment status due to high reinfection rates 1